Donald Zakrowski - Eli Lilly Chief Fin
| LLY Stock | MXN 15,422 5.88 0.04% |
Insider
Donald Zakrowski is Chief Fin of Eli Lilly and
| Phone | 317 276 2000 |
| Web | https://www.lilly.com |
Donald Zakrowski Latest Insider Activity
Tracking and analyzing the buying and selling activities of Donald Zakrowski against Eli Lilly stock is an integral part of due diligence when investing in Eli Lilly. Donald Zakrowski insider activity provides valuable insight into whether Eli Lilly is net buyers or sellers over its current business cycle. Note, Eli Lilly insiders must abide by specific rules, including filing SEC forms every time they buy or sell Eli Lilly'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Donald Zakrowski over a year ago Payment of 2142 shares by Donald Zakrowski of Eli Lilly subject to Rule 16b-3 | ||
Donald Zakrowski over a year ago Sale by Donald Zakrowski of 670 shares of Eli Lilly |
Eli Lilly Management Efficiency
The company has return on total asset (ROA) of 0.1148 % which means that it generated a profit of $0.1148 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.6464 %, meaning that it generated $0.6464 on every $100 dollars invested by stockholders. Eli Lilly's management efficiency ratios could be used to measure how well Eli Lilly manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Cristal Downing | Merck Company | 54 | |
| Pascale Schmidt | Roche Holding AG | 50 | |
| Deborah Telman | Gilead Sciences | 58 | |
| Christopher Viehbacher | Biogen Inc | 63 | |
| Thomas Schinecker | Roche Holding AG | 48 | |
| BCH BM | Bristol Myers Squibb | 57 | |
| Bruno Eschli | Roche Holding AG | N/A | |
| David MD | Amgen Inc | 60 | |
| Lisa LeCointeCephas | Merck Company | 41 | |
| Linda Higgins | Gilead Sciences | 61 | |
| Peter Dannenbaum | Merck Company | N/A | |
| Nicole Murphy | Biogen Inc | N/A | |
| Caroline Litchfield | Merck Company | 54 | |
| Sandra Esq | Bristol Myers Squibb | 62 | |
| Cari Gallman | Bristol Myers Squibb | N/A | |
| Natacha Gassenbach | Biogen Inc | N/A | |
| Jacquie CFA | Gilead Sciences | N/A | |
| Jyoti Mehra | Gilead Sciences | 47 | |
| Nancy Grygiel | Amgen Inc | 55 | |
| Timothy Power | Bristol Myers Squibb | N/A | |
| Giovanni MD | Bristol Myers Squibb | 58 | |
Management Performance
| Return On Equity | 0.65 | |||
| Return On Asset | 0.11 |
Eli Lilly Leadership Team
Elected by the shareholders, the Eli Lilly's board of directors comprises two types of representatives: Eli Lilly inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Eli. The board's role is to monitor Eli Lilly's management team and ensure that shareholders' interests are well served. Eli Lilly's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Eli Lilly's outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Ricks, Senior Vice President and Presidentident - Lilly Bio-Medicines | ||
| Alonzo Weems, VP Officer | ||
| Jacob Naarden, CEO VP | ||
| Diogo Rau, VP Officer | ||
| Donald Zakrowski, Chief Fin | ||
| Anat Ashkenazi, VP CFO | ||
| Leigh Pusey, Senior Vice President - Corporate Affairs and Communications | ||
| Martin MIBS, VP Projects | ||
| Anat JD, Gen VP |
Eli Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Eli Lilly a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.65 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.22 % | |||
| Operating Margin | 0.29 % | |||
| Current Valuation | 6.99 T | |||
| Shares Outstanding | 950.18 M | |||
| Shares Owned By Insiders | 0.15 % | |||
| Shares Owned By Institutions | 85.00 % | |||
| Price To Earning | 333.06 X | |||
| Price To Book | 34.76 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Eli Stock Analysis
When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.